The α4β7 blockade with vedolizumab is effective in prevention of graft vs. host disease using a xenogeneic mouse model

Senthilnathan Palaniyandi; Reena Kumari; Ethan Strattan; Timothy Huang; Jing Du; Natalya Hakim; Melissa V. Kesler; Gerhard C. Hildebrandt

doi:10.1002/ajh.25678

The α4β7 blockade with vedolizumab is effective in prevention of graft vs. host disease using a xenogeneic mouse model

Senthilnathan Palaniyandi
, Reena Kumari
, Ethan Strattan
, Timothy Huang
, Jing Du
, Natalya Hakim
, Melissa V. Kesler
, Gerhard C. Hildebrandt

Producción científica: Letter › revisión exhaustiva

4 Citas (Scopus)

Idioma original	English
Páginas (desde-hasta)	E39-E41
Publicación	American Journal of Hematology
Volumen	95
N.º	2
DOI	https://doi.org/10.1002/ajh.25678
Estado	Published - feb 1 2020

Nota bibliográfica

Funding Information:
This study was funded by TAKEDA Pharmaceuticals U.S.A through IISR grant (SP and GCH). This research was supported by the Biospecimen Procurement & Translational Pathology Shared Resource Facility and Flow Cytometry and Cell Sorting Core Facility: Supported by the Markey Cancer Center and an NCI Center Core Support Grant (P30CA177558).

Funding Information:
This study was funded by TAKEDA Pharmaceuticals U.S.A through IISR grant (SP and GCH). This research was supported by the Biospecimen Procurement & Translational Pathology Shared Resource Facility and Flow Cytometry and Cell Sorting Core Facility: Supported by the Markey Cancer Center and an NCI Center Core Support Grant (P30CA177558).

Financiación

This study was funded by TAKEDA Pharmaceuticals U.S.A through IISR grant (SP and GCH). This research was supported by the Biospecimen Procurement & Translational Pathology Shared Resource Facility and Flow Cytometry and Cell Sorting Core Facility: Supported by the Markey Cancer Center and an NCI Center Core Support Grant (P30CA177558). This study was funded by TAKEDA Pharmaceuticals U.S.A through IISR grant (SP and GCH). This research was supported by the Biospecimen Procurement & Translational Pathology Shared Resource Facility and Flow Cytometry and Cell Sorting Core Facility: Supported by the Markey Cancer Center and an NCI Center Core Support Grant (P30CA177558).

Financiadores	Número del financiador
Biospecimen Procurement & Translational Pathology Shared Resource Facility
IISR
Markey Cancer Center
Markey Cancer Center NCI
National Childhood Cancer Registry – National Cancer Institute	P30CA177558
Center for Outcomes Research and Evaluation, Yale School of Medicine
Takeda Pharmaceuticals U.S.A.
University of Kentucky Markey Comprehensive Cancer Center

ASJC Scopus subject areas

Hematology

Acceder al documento

10.1002/ajh.25678

Otros archivos y enlaces

Citar esto

@article{0e05411d6b664f518be825aa3ccfe3b2,

title = "The α4β7 blockade with vedolizumab is effective in prevention of graft vs. host disease using a xenogeneic mouse model",

author = "Senthilnathan Palaniyandi and Reena Kumari and Ethan Strattan and Timothy Huang and Jing Du and Natalya Hakim and Kesler, \{Melissa V.\} and Hildebrandt, \{Gerhard C.\}",

note = "Funding Information: This study was funded by TAKEDA Pharmaceuticals U.S.A through IISR grant (SP and GCH). This research was supported by the Biospecimen Procurement \& Translational Pathology Shared Resource Facility and Flow Cytometry and Cell Sorting Core Facility: Supported by the Markey Cancer Center and an NCI Center Core Support Grant (P30CA177558). Funding Information: This study was funded by TAKEDA Pharmaceuticals U.S.A through IISR grant (SP and GCH). This research was supported by the Biospecimen Procurement \& Translational Pathology Shared Resource Facility and Flow Cytometry and Cell Sorting Core Facility: Supported by the Markey Cancer Center and an NCI Center Core Support Grant (P30CA177558).",

year = "2020",

month = feb,

day = "1",

doi = "10.1002/ajh.25678",

language = "English",

volume = "95",

pages = "E39--E41",

number = "2",

}

TY - JOUR

T1 - The α4β7 blockade with vedolizumab is effective in prevention of graft vs. host disease using a xenogeneic mouse model

AU - Palaniyandi, Senthilnathan

AU - Kumari, Reena

AU - Strattan, Ethan

AU - Huang, Timothy

AU - Du, Jing

AU - Hakim, Natalya

AU - Kesler, Melissa V.

AU - Hildebrandt, Gerhard C.

N1 - Funding Information: This study was funded by TAKEDA Pharmaceuticals U.S.A through IISR grant (SP and GCH). This research was supported by the Biospecimen Procurement & Translational Pathology Shared Resource Facility and Flow Cytometry and Cell Sorting Core Facility: Supported by the Markey Cancer Center and an NCI Center Core Support Grant (P30CA177558). Funding Information: This study was funded by TAKEDA Pharmaceuticals U.S.A through IISR grant (SP and GCH). This research was supported by the Biospecimen Procurement & Translational Pathology Shared Resource Facility and Flow Cytometry and Cell Sorting Core Facility: Supported by the Markey Cancer Center and an NCI Center Core Support Grant (P30CA177558).

PY - 2020/2/1

Y1 - 2020/2/1

UR - https://www.scopus.com/pages/publications/85076402849

UR - https://www.scopus.com/pages/publications/85076402849#tab=citedBy

U2 - 10.1002/ajh.25678

DO - 10.1002/ajh.25678

M3 - Letter

C2 - 31724186

AN - SCOPUS:85076402849

SN - 0361-8609

VL - 95

SP - E39-E41

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 2

ER -

The α4β7 blockade with vedolizumab is effective in prevention of graft vs. host disease using a xenogeneic mouse model

Nota bibliográfica

Financiación

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto